| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Phase 1/2 | BioNTech SE | Basking Ridge |
| A Dietary Study for People With Multiple Myeloma | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Registry for People With Lung Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Collecting Health Information to Understand and Prevent Gastric Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 177Lu-PSMA-617 in People With Gliomas | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Armored CAR T Cells in People With Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Blood Pressure Control During Cancer Treatment | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of CRD3874-SI in People With Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of CRD3874-SI in People With Solid Tumors | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC) | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Changes to Prostate Procedures | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Counseling Support for Cancer Survivors Age 65+ | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | Basking Ridge |
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ear Nerve Stimulation to Treat Eye Inflammation | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Herbal Supplements in Cancer Survivors With Constipation | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Hospital-at-Home for People Receiving Tarlatamab | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Isoquercetin in People With Ovarian Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ivonescimab in People With Leiomyosarcoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ivonescimab in People With Non-Small Cell Lung Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Language Interpretation Solutions for People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Lower Dose Radiation Therapy for People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Lung Cancer Risk | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Lung Cancer Screening in People With Unexplained Weight Loss | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Meaning-Centered Psychotherapy for Caregivers to People With Cancer | N/A | Icahn School of Medicine at Mount Sinai | Basking Ridge |
| A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Mirdametinib in People With Central Nervous System Tumors | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Multiparametric Ultrasound Imaging Methods | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Music Therapy for Anxiety in People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pasireotide in People With Prolactinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pembrolizumab in People With Ultra-Rare Sarcomas | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Questionnaires in Adolescents and Young Adults With Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Revaree Plus in People With Breast Cancer | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Revumenib and Mezigdomide in People With Leukemia | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Romosozumab in People With Breast Cancer and Osteoporosis | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of SER-155 to Treat Diarrhea in People on Immunotherapy | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Sacituzumab Govitecan in People With Mesothelioma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | Early 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Skipping Radiation Therapy in People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Sotorasib in People With Brain Tumors | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Sotorasib in People With Non-Small Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Surgery and Radiotherapy in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Surgical Techniques During Cystectomy | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | Phase 2 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Tarlatamab for People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Treatment Delivery Preference In People With Kidney Cancer | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | Basking Ridge |
| A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of ZEN003694 in People With Squamous Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. | Phase 2 | Taiho Oncology, Inc. | Basking Ridge |
| A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Decision Tool for People Considering Breast Reconstruction Surgery | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a New PET Scanner in People With Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Side Effects and Resource Navigation Program for People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of an Anxiety Intervention for Latino/Latina/Hispanic Older Adults With Cancer and Their Caregivers | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of the Use of 3D Technology to Guide Head and Neck Surgery | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | Phase 2 | City of Hope Medical Center | Basking Ridge |
| A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Phase 3 | Taiho Oncology, Inc. | Basking Ridge |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | Basking Ridge |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | Basking Ridge |
| A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | Phase 3 | Pfizer | Basking Ridge |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Phase 3 | Pfizer | Basking Ridge |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | Basking Ridge |
| A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | Basking Ridge |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Acupuncture for People Experiencing Period Loss Due to Chemotherapy | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Collecting Information About Treatment Results for Patients With Cushing's Syndrome | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Collection of Information to Better Understand Young Onset Colorectal Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | Basking Ridge |
| Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer | N/A | Ponce Medical School Foundation, Inc. | Basking Ridge |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | Basking Ridge |
| Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Factors Associated With Breast Cancer Risks and Outcomes | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Genomic Profiling in Cancer Patients | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Germ Cell Tumor and Testicular Tumor DNA Registry | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Glioma Developmental and HyperActive Ras Tumor (DHART) Board | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Groningen International Study on Sentinel Nodes in Vulvar Cancer-III | Phase 2 | University Medical Center Groningen | Basking Ridge |
| HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Impact of ICCAN on Cancer Treatment Completion and Quality of Life | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | Basking Ridge |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | Early 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Kidney Cancer DNA Registry | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | Basking Ridge |
| Lymphedema Surveillance Study | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Malignant Polyp Registry | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | Basking Ridge |
| Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | Phase 3 | Canadian Cancer Trials Group | Basking Ridge |
| Normative Ranges of Lingual Strength and Endurance and the Impact of the IOPI Lingual Strength Trainer on Quantitative Functional Outcomes and Patient-Reported Outcomes After Partial Glossectomy or Hemiglossectomy for Oral Tongue Cancer, An Unblinded: Randomized Pilot Study | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | Basking Ridge |
| Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Phase 2 | Dana-Farber Cancer Institute | Basking Ridge |
| Radiation Therapy Approaches for People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Registry Study of People Who Are Having an Esophagectomy and Are at High Risk of Anastomotic Leak | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Researching the Effect of Exercise on Cancer | N/A | City of Hope Medical Center | Basking Ridge |
| Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of Aerobic Training for People Receiving Treatment for Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) | Phase 3 | AstraZeneca | Basking Ridge |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Phase 1/2 | Pfizer | Basking Ridge |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | Basking Ridge |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer | Phase 2 | Pfizer | Basking Ridge |
| Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Basking Ridge |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | Phase 3 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | Basking Ridge |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | Basking Ridge |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | Basking Ridge |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | Basking Ridge |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | Basking Ridge |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | Basking Ridge |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Phase 2 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | Basking Ridge |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity | Phase 2/3 | ECOG-ACRIN Cancer Research Group | Basking Ridge |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | Basking Ridge |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | Phase 2 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | Phase 1 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | Phase 1 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | Basking Ridge |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | Basking Ridge |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Phase 4 | Pfizer | Basking Ridge |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Phase 3 | Pfizer | Basking Ridge |
| Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Ulixertinib in People With Histiocytic Neoplasms | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Using Urine Samples to Identify Lung Cancer | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Basking Ridge |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | Basking Ridge |
| [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | Belleville |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | Belleville |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | Phase 3 | Merck Sharp & Dohme LLC | Belleville |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | Belleville |
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | Immuneering Corporation | Belleville |
| DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment | Phase 4 | Rutgers, The State University of New Jersey | Belleville |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | LeonaBio | Belleville |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | Belleville |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | Belleville |
| RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | Phase 1 | Mridula George, MD | Belleville |
| TEMPUS ARIES: A Biobank Registry Platform Study in Oncology | — | Tempus AI | Belleville |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | Belleville |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | Berkeley Heights |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | Berkeley Heights |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | Corxel Pharmaceuticals | Berlin |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | Berlin |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) | Phase 3 | Merck Sharp & Dohme LLC | Bloomfield |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema | Phase 2/3 | AbbVie | Bloomfield |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | Phase 2 | Bio-Path Holdings, Inc. | Brick |
| Leveraging the Emergency Department (LEAD) Study | N/A | Hackensack Meridian Health | Brick |
| Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer | — | Rutgers, The State University of New Jersey | Brick |
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | Phase 3 | National Cancer Institute (NCI) | Brick |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | Bridgewater |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | Phase 3 | AstraZeneca | Bridgewater |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | Bridgewater |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | Bridgewater |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | Bridgewater |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | Bridgewater |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | Bridgewater |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | Bridgewater |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | Bridgewater |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | Bridgewater |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | Bridgewater |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease | Phase 3 | Exelixis | Bridgewater |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | Browns Mills |
| Alleviant ALLAY-HFrEF Study | N/A | Alleviant Medical, Inc. | Browns Mills |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | Browns Mills |
| CCM OPEN HF Registry | — | Impulse Dynamics | Browns Mills |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | Browns Mills |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | N/A | Cardiac Dimensions, Inc. | Browns Mills |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | Phase 3 | AstraZeneca | Camden |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | Camden |
| A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) | Early 1 | Roger Strair | Camden |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | Phase 3 | Hoffmann-La Roche | Camden |
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression | Phase 3 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Camden |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | Camden |
| A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer | Phase 2 | AbbVie | Camden |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | Camden |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | Camden |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | Camden |
| A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | Phase 2 | Novartis Pharmaceuticals | Camden |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | Phase 3 | AstraZeneca | Camden |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | Camden |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | Camden |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | Camden |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | Camden |
| Effects of Oncological Treatment During Pregnancy on Mother and Child | — | University Hospital, Gasthuisberg | Camden |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | Camden |
| Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial | Phase 3 | M.D. Anderson Cancer Center | Camden |
| Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy | N/A | The Cooper Health System | Camden |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | Camden |
| Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes | — | The Cooper Health System | Camden |
| Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study | — | M.D. Anderson Cancer Center | Camden |
| Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma | Phase 2 | M.D. Anderson Cancer Center | Camden |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Phase 4 | Pfizer | Camden |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | Camden |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | Camden |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Phase 3 | Summit Therapeutics | Camden |
| Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) | N/A | Supira Medical | Camden |
| Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. | Phase 2 | The Cooper Health System | Camden |
| Prevail Global Study | N/A | Medtronic Vascular | Camden |
| Product Surveillance Registry | — | Medtronic | Camden |
| Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy | N/A | The Cooper Health System | Camden |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | Camden |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | Camden |
| SPYRAL GEMINI Pilot Study | N/A | Medtronic Vascular | Camden |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | Camden |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | AstraZeneca | Camden |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | Camden |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | N/A | Natera, Inc. | Camden |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | Camden |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | Camden |
| Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome | N/A | The Cooper Health System | Camden |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Phase 3 | Bausch Health Americas, Inc. | Camden |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | Camden |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | Camden |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | Camden |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | Phase 2 | National Cancer Institute (NCI) | Camden |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | Camden |
| Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery | N/A | Unity Health Toronto | Camden |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | Camden |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | Cape May Court House |
| Focused Extracorporeal Shockwave Therapy for Knee Arthritis | N/A | Kessler Foundation | Cedar Knolls |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | Cherry Hill |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | Cherry Hill |
| A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder | Phase 2 | Astellas Pharma Global Development, Inc. | Cherry Hill |
| A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder | Phase 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Cherry Hill |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | Cherry Hill |
| COPD Exacerbation Follow Up | — | Viz.ai, Inc. | Cherry Hill |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | Cherry Hill |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Phase 3 | Axsome Therapeutics, Inc. | Cherry Hill |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | Cherry Hill |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Cherry Hill |
| Multiple Sclerosis Implementation Network (Registry) | — | The University of Texas Health Science Center, Houston | Cherry Hill |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | Cherry Hill |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | Cherry Hill |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | Phase 3 | National Cancer Institute (NCI) | Cherry Hill |
| Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | Phase 3 | Alliance for Clinical Trials in Oncology | Cherry Hill |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | Cherry Hill |
| Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery | N/A | Thomas Jefferson University | Cherry Hill |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | Cherry Hill |
| Persona Revision Knee System Outcomes | — | Zimmer Biomet | Chester |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | Clark |
| Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial | N/A | Palette Life Sciences, Inc. | Clifton |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | Clifton |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Phase 1 | AVEO Pharmaceuticals, Inc. | East Brunswick |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | East Brunswick |
| A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | Phase 1 | EpiBiologics | East Brunswick |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | East Brunswick |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | East Brunswick |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Phase 2 | Verastem, Inc. | East Brunswick |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Phase 2 | Verastem, Inc. | East Brunswick |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Phase 2 | Verastem, Inc. | East Brunswick |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | Phase 1/2 | Hutchmed | East Brunswick |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | East Brunswick |
| A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) | Phase 3 | Genentech, Inc. | East Brunswick |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | East Brunswick |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | East Brunswick |
| A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Flare Therapeutics Inc. | East Brunswick |
| A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Phase 1 | Ascentage Pharma Group Inc. | East Brunswick |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | East Brunswick |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | East Brunswick |
| A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer | Phase 1/2 | GlaxoSmithKline | East Brunswick |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | East Brunswick |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | East Brunswick |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | East Brunswick |
| A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | East Brunswick |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | East Brunswick |
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Phase 1 | Cogent Biosciences, Inc. | East Brunswick |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | East Brunswick |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | East Brunswick |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | East Brunswick |
| A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | East Brunswick |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | East Brunswick |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | East Brunswick |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | AbbVie | East Brunswick |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | East Brunswick |
| A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | East Brunswick |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Phase 1 | Allogene Therapeutics | East Brunswick |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | East Brunswick |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Phase 1/2 | Boehringer Ingelheim | East Brunswick |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | Phase 3 | BeOne Medicines | East Brunswick |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | Phase 3 | SystImmune Inc. | East Brunswick |
| Behavioral Exposure for Introceptive Tolerance RCT | N/A | Rutgers, The State University of New Jersey | East Brunswick |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | East Brunswick |
| DBC-664 in Adult Patients With Solid Tumors | Phase 1 | Duboce Biopharmaceuticals, Inc. | East Brunswick |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Phase 2 | Merck Sharp & Dohme LLC | East Brunswick |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | East Brunswick |
| FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | Phase 1/2 | Gilead Sciences | East Brunswick |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Phase 1/2 | Daiichi Sankyo | East Brunswick |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer | Phase 1/2 | AstraZeneca | East Brunswick |
| HMPL-A830 in Solid Tumors | Phase 1/2 | Hutchmed | East Brunswick |
| IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | Phase 1 | Fortvita Biologics (USA)Inc. | East Brunswick |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | East Brunswick |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | East Brunswick |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | East Brunswick |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | East Brunswick |
| RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive | Phase 2/3 | Hoffmann-La Roche | East Brunswick |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 2 | Corcept Therapeutics | East Brunswick |
| SLV-154 Treatment of Advanced Cancers | Phase 1 | Solve Therapeutics | East Brunswick |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02) | Phase 2/3 | BioNTech SE | East Brunswick |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Phase 3 | Novartis Pharmaceuticals | East Brunswick |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | Phase 3 | AstraZeneca | East Brunswick |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | East Brunswick |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Phase 2 | AstraZeneca | East Brunswick |
| Study of GS-2426 in Participants With Advanced Solid Tumors | Phase 1 | Gilead Sciences | East Brunswick |
| Study of Oral MRT-2359 With Apalutamide in Prostate Cancer | Phase 2 | Monte Rosa Therapeutics, Inc | East Brunswick |
| Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel | Phase 2 | Sironax USA, Inc. | East Brunswick |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | East Brunswick |
| Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | Phase 1/2 | Gilead Sciences | East Brunswick |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Phase 1 | Exelixis | East Brunswick |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) | Phase 3 | Revolution Medicines, Inc. | East Brunswick |
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer | Phase 2 | Genmab | East Brunswick |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | Phase 1/2 | AbbVie | East Brunswick |
| To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer | Phase 2 | Hoffmann-La Roche | East Brunswick |
| Visugromab in Cachexia International Trial | Phase 2/3 | CatalYm GmbH | East Brunswick |
| A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis | N/A | Kessler Foundation | East Hanover |
| A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | — | Novartis Pharmaceuticals | East Hanover |
| A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Novartis Pharmaceuticals | East Hanover |
| A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan | — | Novartis Pharmaceuticals | East Hanover |
| A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | — | Novartis Pharmaceuticals | East Hanover |
| Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons | N/A | Kessler Foundation | East Hanover |
| Pluvicto Real-world Investigation in Survival in Metastatic CRPC | — | Novartis Pharmaceuticals | East Hanover |
| Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community | N/A | Kessler Foundation | East Hanover |
| Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | — | ECOG-ACRIN Cancer Research Group | East Orange |
| ERP to Improve Functioning in Veterans With OCD | N/A | VA Office of Research and Development | East Orange |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | East Orange |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | Eatontown |
| A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Phase 3 | AstraZeneca | Eatontown |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | Eatontown |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | Eatontown |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | Eatontown |
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | Phase 3 | Astellas Pharma Global Development, Inc. | Edison |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | Edison |
| Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS) | N/A | Hackensack Meridian Health | Edison |
| Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | Phase 1/2 | Laminar Pharmaceuticals | Edison |
| RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT | — | The Radiosurgery Society | Egg Harbor |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | Egg Harbor |
| ATATcH Alternating Treatment Plans for Advanced Cancer | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | Elizabeth |
| Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | Elmer |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | Elmer |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | Englewood |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | Englewood |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | Englewood |
| Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects | — | Alliance for Clinical Trials in Oncology | Englewood |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | Englewood |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | Englewood |
| Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy | N/A | Englewood Hospital and Medical Center | Englewood |
| One-Month DAPT in CABG Patients | Phase 3 | Weill Medical College of Cornell University | Englewood |
| Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System- | — | Englewood Hospital and Medical Center | Englewood |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities | Phase 3 | Weill Medical College of Cornell University | Englewood |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women | Phase 3 | Weill Medical College of Cornell University | Englewood |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | Englewood |
| Tempus Small Cell Lung Cancer Observational Study (Sculptor) | — | Tempus AI | Englewood |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | Englewood |
| Ultralow Dose PET Imaging for 18F-NaF Uptake | Phase 2 | Akiva Mintz | Englewood |
| Ultralow Dose PET Imaging for PSMA Expression | Phase 2 | Akiva Mintz | Englewood |
| Ultralow Dose PET Imaging of 18F-FDG Uptake | Phase 2 | Akiva Mintz | Englewood |
| Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol | Phase 2 | Akiva Mintz | Englewood |
| Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake | Phase 2 | Akiva Mintz | Englewood |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Phase 1/2 | VM Oncology, LLC | Englewood |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | Flemington |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | Flemington |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | Flemington |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | Flemington |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | Flemington |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | Flemington |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | Hoffmann-La Roche | Florham Park |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | Florham Park |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies | Phase 2 | Curis, Inc. | Florham Park |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | Florham Park |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | Hoffmann-La Roche | Florham Park |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | N/A | Novian Health Inc. | Florham Park |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | — | Tempus AI | Florham Park |
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | Phase 2 | Oncolytics Biotech | Florham Park |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | Florham Park |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Phase 2 | AbbVie | Florham Park |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | Freehold |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Phase 1/2 | Hoffmann-La Roche | Freehold |
| Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | N/A | ECOG-ACRIN Cancer Research Group | Freehold |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | Freehold |
| Clinical Trial for Integrated Care to Help At Risk Teen (iCHART) Intervention | N/A | University of Pittsburgh | Gibbsboro |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | Phase 1/2 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | Phase 2 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) | Phase 1 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Phase 2/3 | Merck Sharp & Dohme LLC | Hackensack |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | Hackensack |
| A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | Phase 1 | BeOne Medicines | Hackensack |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Phase 1 | Kyowa Kirin, Inc. | Hackensack |
| A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Phase 1/2 | Blueprint Medicines Corporation | Hackensack |
| A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) | Phase 1 | Moonlight Bio, Inc | Hackensack |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | Hackensack |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Sanofi | Hackensack |
| A Global Study of the PETAL Consortium | — | Massachusetts General Hospital | Hackensack |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | Hackensack |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | Hackensack |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | Hackensack |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | Hackensack |
| A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | Phase 1 | Regeneron Pharmaceuticals | Hackensack |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | Hackensack |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | LigaChem Biosciences, Inc. | Hackensack |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | Hackensack |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 1 | Orca Biosystems, Inc. | Hackensack |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Phase 1/2 | Nkarta, Inc. | Hackensack |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Phase 1/2 | BeOne Medicines | Hackensack |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | Hackensack |
| A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | Phase 1 | NextCure, Inc. | Hackensack |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Phase 2 | Georgetown University | Hackensack |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | Hackensack |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | Hackensack |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | Hackensack |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | Hackensack |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | Hackensack |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | Hackensack |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | Hackensack |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | Hackensack |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | Hackensack |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | Hackensack |
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab | Phase 1 | Boehringer Ingelheim | Hackensack |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | Hackensack |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | Hackensack |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | Hackensack |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Phase 1/2 | AstraZeneca | Hackensack |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | Hackensack |
| A Study of BG-C477 in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | Hackensack |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | Phase 1 | Bristol-Myers Squibb | Hackensack |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | Hackensack |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | Hackensack |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | Hackensack |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Phase 1 | Merck Sharp & Dohme LLC | Hackensack |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | Hackensack |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Astellas Pharma Global Development, Inc. | Hackensack |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 2 | Incyte Corporation | Hackensack |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | Hackensack |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | Hackensack |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Phase 2 | Merck Sharp & Dohme LLC | Hackensack |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | Hackensack |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Phase 1 | Pfizer | Hackensack |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Phase 3 | Ascentage Pharma Group Inc. | Hackensack |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | Hackensack |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | Phase 2 | Hackensack Meridian Health | Hackensack |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | Phase 3 | AstraZeneca | Hackensack |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Phase 1/2 | Novartis Pharmaceuticals | Hackensack |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | Hackensack |
| A Study of ZW251 in Participants With Advanced Solid Tumors | Phase 1 | Zymeworks BC Inc. | Hackensack |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | Hackensack |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | Hackensack |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | Hackensack |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | Hackensack |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | Hackensack |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1/2 | Celgene | Hackensack |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Incyte Corporation | Hackensack |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | Hackensack |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | Phase 1/2 | AstraZeneca | Hackensack |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | Kelonia Therapeutics, Inc. | Hackensack |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | Hackensack |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | Phase 2 | Hoffmann-La Roche | Hackensack |
| A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Phase 1/2 | Merck Sharp & Dohme LLC | Hackensack |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | Phase 1/2 | Merck Sharp & Dohme LLC | Hackensack |
| A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Incyte Corporation | Hackensack |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Hackensack |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | Phase 1 | Bristol-Myers Squibb | Hackensack |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Phase 1 | Astellas Pharma Inc | Hackensack |
| A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | Hackensack |
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | Hackensack |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | Hackensack |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | Hackensack |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | Hackensack |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | Phase 1 | Regeneron Pharmaceuticals | Hackensack |
| A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | Phase 1 | Boehringer Ingelheim | Hackensack |
| AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor | — | Peerbridge Health, Inc | Hackensack |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Phase 1/2 | UniQure Biopharma B.V. | Hackensack |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | Phase 1/2 | AstraZeneca | Hackensack |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | Hackensack |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | Hackensack |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | Caribou Biosciences, Inc. | Hackensack |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression | Phase 1 | Context Therapeutics Inc. | Hackensack |
| Cardiogenic Shock Working Group Registry | — | Tufts Medical Center | Hackensack |
| Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma | Phase 1 | Hackensack Meridian Health | Hackensack |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | Hackensack |
| Clinical Trial of Approaches to Prostate Cancer Surgery | N/A | Weill Medical College of Cornell University | Hackensack |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | Hackensack |
| Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma | Phase 3 | ECOG-ACRIN Cancer Research Group | Hackensack |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | Hackensack |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | Hackensack |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Phase 2 | Giselle Sholler | Hackensack |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | Hackensack |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | Hackensack |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | Hackensack |
| ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes | — | Hackensack Meridian Health | Hackensack |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | Hackensack |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | Hackensack |
| Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | Phase 3 | NYU Langone Health | Hackensack |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | Hackensack |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Phase 1/2 | Milton S. Hershey Medical Center | Hackensack |
| Embryonal Tumor With Multilayered Rosettes | Phase 2 | University of California, San Francisco | Hackensack |
| Empathic Communication Skills (ECS) Training | N/A | Memorial Sloan Kettering Cancer Center | Hackensack |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | Phase 2 | Academic and Community Cancer Research United | Hackensack |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Phase 2 | Daiichi Sankyo | Hackensack |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | Hackensack |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | Hackensack |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | Hackensack |
| First in Human, Dose Escalation Study of AN4005 | Phase 1 | Adlai Nortye Biopharma Co., Ltd. | Hackensack |
| Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies | Phase 2 | Hackensack Meridian Health | Hackensack |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Phase 1/2 | Vironexis Biotherapeutics Inc. | Hackensack |
| Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment | — | Montefiore Medical Center | Hackensack |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | — | Stanford University | Hackensack |
| INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery | N/A | Abiomed Inc. | Hackensack |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | Hackensack |
| Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma | Phase 2 | Hackensack Meridian Health | Hackensack |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | Hackensack |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | Hackensack |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | Hackensack |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | Hackensack |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | Phase 2 | Hackensack Meridian Health | Hackensack |
| OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression | N/A | Hackensack Meridian Health | Hackensack |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | Hackensack |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Phase 2 | Pulmotect, Inc. | Hackensack |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | Hackensack |
| Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | — | St. Jude Children's Research Hospital | Hackensack |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | Hackensack |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | Phase 2 | Georgetown University | Hackensack |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Phase 1 | Xencor, Inc. | Hackensack |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | Hackensack |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | Hackensack |
| Phase IB/II of CPX-351 for Relapse Prevention in AML | Phase 1/2 | Georgetown University | Hackensack |
| Pivotal Study for the Cardiac Performance System (CPS) | — | Sensydia Corporation | Hackensack |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2/3 | TuHURA Biosciences, Inc. | Hackensack |
| Post-operative Urinary Retention (POUR) Following Thoracic Surgery | Phase 1/2 | Hackensack Meridian Health | Hackensack |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | Hackensack |
| Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease | N/A | Herrick Medical LLC | Hackensack |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | Phase 1/2 | Georgetown University | Hackensack |
| RAPA-201 Therapy of Solid Tumors | Phase 1/2 | Rapa Therapeutics LLC | Hackensack |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | Hackensack |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase 1/2 | Karyopharm Therapeutics Inc | Hackensack |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Phase 1/2 | Milton S. Hershey Medical Center | Hackensack |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies | Phase 3 | CSL Behring | Hackensack |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Phase 3 | Corvus Pharmaceuticals, Inc. | Hackensack |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | Hackensack |
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Phase 1 | Whitehawk Therapeutics, Inc. | Hackensack |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | Hackensack |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | Hackensack |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | Hackensack |
| Study of Olverembatinib (HQP1351) in Patients With CML-CP | Phase 3 | Ascentage Pharma Group Inc. | Hackensack |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | Hackensack |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | Hackensack |
| Study of SGR-1505 in Mature B-Cell Neoplasms | Phase 1 | Schrödinger, Inc. | Hackensack |
| Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 1 | SIRPant Immunotherapeutics, Inc. | Hackensack |
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Phase 2 | Black Diamond Therapeutics, Inc. | Hackensack |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1/2 | ModernaTX, Inc. | Hackensack |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Phase 1/2 | Impact Therapeutics, Inc. | Hackensack |
| Support for Cancer Patients Awaiting News | N/A | Hackensack Meridian Health | Hackensack |
| Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Phase 1/2 | Pfizer | Hackensack |
| Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma | Phase 2 | University of California, San Francisco | Hackensack |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | Hackensack |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | Phase 2 | National Cancer Institute (NCI) | Hackensack |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | Hackensack |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | Hackensack |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | Hackensack |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Hackensack |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | Hackensack |
| The HEARTFELT Study | N/A | Heartfelt Technologies | Hackensack |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | Hackensack |
| The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Phase 2 | Children's Hospital Medical Center, Cincinnati | Hackensack |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | Hackensack |
| Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | Phase 1 | Vanda Pharmaceuticals | Hackensack |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | Hackensack |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 2 | Orca Biosystems, Inc. | Hackensack |
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis | Phase 3 | Duke University | Hackensack |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | Hackensack |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | Hackensack |
| Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment | N/A | Hackensack Meridian Health | Hackensack |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | Hackensack |
| XTX301 in Patients With Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | Hackensack |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | — | SWOG Cancer Research Network | Hackettstown |
| ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 | Phase 3 | Milestone Pharmaceuticals Inc. | Haddon Heights |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | Haddon Heights |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | Hamilton |
| Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery | Phase 2 | Howard S. Hochster, MD | Hamilton |
| Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas | Phase 2 | Rutgers, The State University of New Jersey | Hamilton |
| Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD | Phase 2 | Altesa Biosciences, Inc. | Hamilton |
| sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) | Phase 2 | Rutgers, The State University of New Jersey | Hamilton |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | Irvington |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | Jackson |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | Jersey City |
| A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial) | N/A | Fundación EPIC | Jersey City |
| A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Phase 3 | Ascletis Pharma (China) Co., Limited | Jersey City |
| A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Jersey City |
| IVUS CHIP UPP Registry | — | ECRI bv | Jersey City |
| Innovations in Genicular Outcomes Registry | — | Pacira Pharmaceuticals, Inc | Jersey City |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | Jersey City |
| SuperSaturated Oxygen Comprehensive Observational Registry | — | TherOx | Jersey City |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Jersey City |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | Lawrence |
| Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia | — | Bristol-Myers Squibb | Lawrenceville |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | Livingston |
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Phase 3 | Zenas BioPharma (USA), LLC | Livingston |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | Livingston |
| Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | N/A | Rutgers, The State University of New Jersey | Livingston |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | Phase 3 | SWOG Cancer Research Network | Livingston |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | Livingston |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | Livingston |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | Phase 1/2 | National Cancer Institute (NCI) | Livingston |
| mHealth Mindfulness With Patients With Serious Illness and Their Caregivers | N/A | Rutgers, The State University of New Jersey | Livingston |
| Vitaccess Real MG Registry | — | Vitaccess Ltd | Lumberton |
| A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | Phase 2 | Wayshine Biopharm, Inc. | Manahawkin |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Phase 2 | Pharming Technologies B.V. | Marlboro |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | Marlton |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Phase 1 | Eli Lilly and Company | Marlton |
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder | Phase 3 | Janssen Research & Development, LLC | Marlton |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | Marlton |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | Marlton |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | Marlton |
| Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Phase 2 | Supernus Pharmaceuticals, Inc. | Marlton |
| Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure | — | Impulse Dynamics | Marlton |
| The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal | Phase 3 | The Cooper Health System | Marlton |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Phase 3 | Amgen | Mickleton |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | Middletown |
| A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma | — | Memorial Sloan Kettering Cancer Center | Middletown |
| A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer | N/A | Memorial Sloan Kettering Cancer Center | Middletown |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | Phase 3 | SWOG Cancer Research Network | Middletown |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | Phase 2 | National Cancer Institute (NCI) | Middletown |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | Millburn |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | Millville |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | Millville |
| Brain Activity Changes After Cognitive Behavioral Therapy for Anxiety in Autistic Youth From High-Need Communities | N/A | Montclair State University | Montclair |
| A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Montvale |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility | N/A | Memorial Sloan Kettering Cancer Center | Montvale |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | Moorestown |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Moorestown |
| Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Phase 3 | GlaxoSmithKline | Moorestown |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Moorestown |
| The Radiation Oncology Registry and Biosample Repository | — | Abramson Cancer Center at Penn Medicine | Moorestown |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | Phase 3 | Merck Sharp & Dohme LLC | Morristown |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | Morristown |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Phase 3 | Merck Sharp & Dohme LLC | Morristown |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | Phase 1 | ALX Oncology Inc. | Morristown |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Phase 2 | GlaxoSmithKline | Morristown |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | Morristown |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | Morristown |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Krystal Biotech, Inc. | Morristown |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | Merck Sharp & Dohme LLC | Morristown |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Phase 3 | Daiichi Sankyo | Morristown |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | Phase 3 | Merck Sharp & Dohme LLC | Morristown |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Phase 2/3 | Merck Sharp & Dohme LLC | Morristown |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | Morristown |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | Morristown |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Phase 1 | Pierre Fabre Medicament | Morristown |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | Morristown |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Phase 2/3 | Pfizer | Morristown |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | Morristown |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | Morristown |
| ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | N/A | Edwards Lifesciences | Morristown |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | Morristown |
| ATLAS (AltaValve) Pivotal Trial | N/A | 4C Medical Technologies, Inc. | Morristown |
| Assessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity | — | Atlantic Health System | Morristown |
| CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry | — | Universitätsklinikum Hamburg-Eppendorf | Morristown |
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma | Phase 1/2 | Diakonos Oncology Corporation | Morristown |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | Phase 1/2 | Eikon Therapeutics | Morristown |
| Early Feasibility Study - Edwards APTURE Transcatheter Shunt System | N/A | Edwards Lifesciences | Morristown |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | Morristown |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | Morristown |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | Morristown |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | Morristown |
| L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | Phase 2/3 | Moleculin Biotech, Inc. | Morristown |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | Morristown |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | Morristown |
| Pancreatic Cancer Detection Consortium | — | City of Hope Medical Center | Morristown |
| Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | Phase 1 | Vaxiion Therapeutics | Morristown |
| Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase 2 | Stingray Therapeutics | Morristown |
| Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer | Phase 2 | PrECOG, LLC. | Morristown |
| Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR | — | Atlantic Health System | Morristown |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | Morristown |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | Morristown |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | Morristown |
| Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis | Phase 4 | Atlantic Health System | Morristown |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | Phase 2 | Tiago Biachi de Castria | Morristown |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | Morristown |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | Morristown |
| Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Phase 3 | Syndax Pharmaceuticals | Morristown |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Phase 1/2 | Sellas Life Sciences Group | Morristown |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 | Genmab | Morristown |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | Pfizer | Morristown |
| TVMR With the INNOVALVE System Trial - Early Feasibility Study | N/A | Edwards Lifesciences | Morristown |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | Morristown |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | Morristown |
| Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women | N/A | M.D. Anderson Cancer Center | Morristown |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | Mountain Lakes |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | Phase 3 | AbbVie | Mullica Hill |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | Mullica Hill |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | Mullica Hill |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Phase 2 | Genelux Corporation | Mullica Hill |
| This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization | Phase 4 | Regeneron Pharmaceuticals | Mullica Hill |
| An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | — | Bayer | Multiple Locations |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | Neptune City |
| A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | Phase 4 | Alexion Pharmaceuticals, Inc. | Neptune City |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | Neptune City |
| Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care | Phase 3 | GT Medical Technologies, Inc. | Neptune City |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | Neptune City |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | Neptune City |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | Neptune City |
| A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) | Phase 2 | Merck Sharp & Dohme LLC | New Brunswick |
| A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) | Phase 1/2 | Merck Sharp & Dohme LLC | New Brunswick |
| A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | Phase 1 | Merck Sharp & Dohme LLC | New Brunswick |
| A Mobile Health Intervention Among Hispanics | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | New Brunswick |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | New Brunswick |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Phase 3 | UroGen Pharma Ltd. | New Brunswick |
| A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma. | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | Phase 2 | Criterium, Inc. | New Brunswick |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Phase 1 | Arvinas Inc. | New Brunswick |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | New Brunswick |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer | Phase 1/2 | Janssen Research & Development, LLC | New Brunswick |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | New Brunswick |
| A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | Phase 1 | GlaxoSmithKline | New Brunswick |
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | New Brunswick |
| A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | New Brunswick |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | Phase 1 | Eli Lilly and Company | New Brunswick |
| A Study of Methylprednisolone in People Having Liver Surgery | Phase 3 | Memorial Sloan Kettering Cancer Center | New Brunswick |
| A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | New Brunswick |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | New Brunswick |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | New Brunswick |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | New Brunswick |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | New Brunswick |
| A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC | Phase 2 | ImmVira Pharma Co. Ltd | New Brunswick |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | New Brunswick |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | New Brunswick |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | New Brunswick |
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | Phase 3 | Regeneron Pharmaceuticals | New Brunswick |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | New Brunswick |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | New Brunswick |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | New Brunswick |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | New Brunswick |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Phase 2 | Pfizer | New Brunswick |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | Phase 3 | J-Pharma Co., Ltd. | New Brunswick |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | Phase 2 | John Sfakianos | New Brunswick |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | Phase 1/2 | Regeneron Pharmaceuticals | New Brunswick |
| A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | — | Bayer | New Brunswick |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Phase 1/2 | Regeneron Pharmaceuticals | New Brunswick |
| A Youth-led Intervention to Reduce Healthcare Disparities in Cancer Screening | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults | Phase 2 | Michal Schnaider Beeri, Ph.D. | New Brunswick |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | New Brunswick |
| Abbott Structural Heart Device Registry | — | Abbott Medical Devices | New Brunswick |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | New Brunswick |
| Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Addressing Genomic Disparities in Cancer Survivors | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Phase 2 | Greg Durm, MD | New Brunswick |
| Bright Ideas - CIN Feasibility Study | N/A | The Hospital for Sick Children | New Brunswick |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | New Brunswick |
| Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy | — | Bo Lu | New Brunswick |
| DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | — | Alnylam Pharmaceuticals | New Brunswick |
| Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | Phase 3 | GlaxoSmithKline | New Brunswick |
| Developing and Implementing HPV SCREENED | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | Phase 1/2 | Christian Hinrichs | New Brunswick |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Phase 2 | Christian Hinrichs | New Brunswick |
| Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | New Brunswick |
| Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy | N/A | Northwell Health | New Brunswick |
| Exercise and Intranasal Insulin in Type 2 Diabetes | Phase 2/3 | Rutgers, The State University of New Jersey | New Brunswick |
| Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy | — | Photocure | New Brunswick |
| Extracellular Vesicles, Insulin Action, and Exercise | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | New Brunswick |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | New Brunswick |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | New Brunswick |
| Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Phase 1 | Christian Hinrichs | New Brunswick |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | New Brunswick |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | New Brunswick |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 2 | Juan P. Alderuccio, MD | New Brunswick |
| Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | Early 1 | Rutgers, The State University of New Jersey | New Brunswick |
| Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) | Phase 2 | Rutgers, The State University of New Jersey | New Brunswick |
| MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial | — | University of Southern California | New Brunswick |
| Metabolic Health, Bones and Nuts During Weight Loss in Adults | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | Phase 2 | Brown University | New Brunswick |
| MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Naltrexone and Propranolol Combined With Immunotherapy | Phase 1 | Sarah Weiss | New Brunswick |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | New Brunswick |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | New Brunswick |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Regeneron Pharmaceuticals | New Brunswick |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | New Brunswick |
| Project CARE: CAncer Risk Evaluation | N/A | Anita Y. Kinney, PhD, RN | New Brunswick |
| Reducing Urban Cervical Cancer Disparities | N/A | Fox Chase Cancer Center | New Brunswick |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | Phase 2 | Oana Danciu | New Brunswick |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | New Brunswick |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | New Brunswick |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | Phase 2 | Nuvation Bio Inc. | New Brunswick |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | New Brunswick |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | New Brunswick |
| SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma | Phase 2 | Rutgers, The State University of New Jersey | New Brunswick |
| SilverCloud as a School-Based Intervention for Vulnerable Youth | N/A | NYU Langone Health | New Brunswick |
| Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Spine Oncology Registry | — | Ohio State University Comprehensive Cancer Center | New Brunswick |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | New Brunswick |
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Cellectis S.A. | New Brunswick |
| Study of APR-1051 in Patients With Advanced Solid Tumors | Phase 1 | Aprea Therapeutics | New Brunswick |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | New Brunswick |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Arcus Biosciences, Inc. | New Brunswick |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Revolution Medicines, Inc. | New Brunswick |
| Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | Phase 1 | Generate Biomedicines | New Brunswick |
| Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors | Phase 1 | Gilead Sciences | New Brunswick |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | New Brunswick |
| Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) | Phase 3 | Bristol-Myers Squibb | New Brunswick |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | Phase 1/2 | Merck Sharp & Dohme LLC | New Brunswick |
| Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | Phase 2 | Dustin Deming | New Brunswick |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | Phase 1 | I-Mab Biopharma US Limited | New Brunswick |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Xencor, Inc. | New Brunswick |
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | Phase 2 | Novartis Pharmaceuticals | New Brunswick |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | Phase 3 | Bristol-Myers Squibb | New Brunswick |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | New Brunswick |
| Sun Safe Together: A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | New Brunswick |
| SynKIR-310 for Relapsed/Refractory B-NHL | Phase 1 | Verismo Therapeutics | New Brunswick |
| TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Phase 3 | Immunocore Ltd | New Brunswick |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | New Brunswick |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | Phase 1 | National Cancer Institute (NCI) | New Brunswick |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | Phase 2 | National Cancer Institute (NCI) | New Brunswick |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Phase 1 | National Cancer Institute (NCI) | New Brunswick |
| The Ailliance Post-Market Clinical Study | N/A | Medtronic Spinal and Biologics | New Brunswick |
| The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer | N/A | Weill Medical College of Cornell University | New Brunswick |
| The Salt Study for Heart Failure | N/A | Maya Guglin, MD | New Brunswick |
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | Phase 2 | Rutgers, The State University of New Jersey | New Brunswick |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | New Brunswick |
| Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | New Brunswick |
| A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | Janssen Research & Development, LLC | Newark |
| Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease | Phase 1/2 | NKGen Biotech, Inc. | Newark |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | Newark |
| Exercise to Improve Brain Health in Older African Americans | Phase 2 | Rutgers, The State University of New Jersey | Newark |
| Gait Adaptation Study | Early 1 | Rutgers, The State University of New Jersey | Newark |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | Newark |
| Liver Transplantation in Intrahepatic Cholangiocarcinoma | — | Rutgers, The State University of New Jersey | Newark |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | Newark |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | Newark |
| Reducing Risk for Infective Endocarditis | N/A | Wake Forest University Health Sciences | Newark |
| SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers | N/A | Beth Israel Deaconess Medical Center | Newark |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | Northfield |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment | Phase 3 | AstraZeneca | Northfield |
| A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease | — | Eisai Korea Inc. | Nutley |
| A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease | — | Eisai Inc. | Nutley |
| Mosaic Trial for Stem Cell Transplant Recipients | N/A | Northwestern University | Nutley |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | Oradell |
| Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers | Phase 1/2 | Eluciderm Inc | Oradell |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | Paramus |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | Paramus |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Phase 2 | Merck Sharp & Dohme LLC | Paramus |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | Paramus |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Phase 3 | Hoffmann-La Roche | Paramus |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | Paramus |
| Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy | Phase 3 | SWOG Cancer Research Network | Paramus |
| Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer | Phase 1 | Valley Health System | Paramus |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Phase 1/2 | Genprex, Inc. | Paramus |
| Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA | — | CathVision ApS | Paramus |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | Paramus |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | Phase 2 | Icahn School of Medicine at Mount Sinai | Paramus |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | Pennington |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | Pennington |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | Pennington |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | Pennington |
| A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | Phase 1 | Janssen Research & Development, LLC | Piscataway |
| Rutgers University Study of the Genetics of Blood Cancers | — | Rutgers, The State University of New Jersey | Piscataway |
| Rutgers University Study of the Genetics of Breast Cancer. | — | Rutgers, The State University of New Jersey | Piscataway |
| Rutgers University Study of the Genetics of Pulmonary Hypertension | — | Rutgers, The State University of New Jersey | Piscataway |
| A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials | N/A | Abramson Cancer Center at Penn Medicine | Plainsboro |
| Foundational Programs to Combat Clinician Stress | N/A | Lancaster General Hospital | Plainsboro |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | Plainsboro |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | Pomona |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | Pomona |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | Princeton |
| Brexanolone Lifting Outcomes Of Moms | Phase 3 | Lipocine Inc. | Princeton |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Phase 1 | Cellectar Biosciences, Inc. | Princeton |
| Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | Phase 1 | Novartis Pharmaceuticals | Princeton |
| Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Phase 1/2 | Molecular Partners AG | Princeton |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | Princeton |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | Ridgewood |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | Ridgewood |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | Ridgewood |
| A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Phase 2 | Candel Therapeutics, Inc. | Saddle Brook |
| A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice | — | Sanofi | Sewell |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | Sewell |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | Sewell |
| CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes | N/A | Thomas Jefferson University | Sewell |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | Sewell |
| Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery | N/A | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sewell |
| Renal Denervation + PVI vs PVI Alone for Persistent AF | N/A | University of Rochester | Short Hills |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | Incyte Corporation | Short Hills |
| Safety and Effectiveness of the HIT Reverse HRS | N/A | Hip Innovation Technology | Somers Point |
| A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Somerset |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | Somerset |
| Registry Study for Radiation Therapy Outcomes | — | Proton Collaborative Group | Somerset |
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Phase 2 | Crystalys Therapeutics | Sparta |
| Caris Biorepository Research Protocol | — | Caris Science, Inc. | Sparta |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Phase 3 | Eli Lilly and Company | Springfield |
| A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease | Phase 2 | Sanofi | Springfield |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer | Phase 1/2 | Engeneic Pty Limited | Summit |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | Summit |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | Summit |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | Summit |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | Summit |
| Collection of Sputum and Labeling for Lung Cancer | — | bioAffinity Technologies Inc. | Summit |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Phase 3 | Daiichi Sankyo | Summit |
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | Phase 2 | AbbVie | Teaneck |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | Teaneck |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | Teaneck |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | Novartis Pharmaceuticals | Teaneck |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | Teaneck |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Phase 3 | Sanofi | Teaneck |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | Toms River |
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | Phase 1 | Eli Lilly and Company | Toms River |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | Toms River |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Toms River |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | Toms River |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | Toms River |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | Toms River |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Toms River |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | Toms River |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Phase 2 | Alto Neuroscience | Toms River |
| ALTO-207 in Adults With Treatment-resistant Depression (TRD) | Phase 2 | Alto Neuroscience | Toms River |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Toms River |
| Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase 2 | GlaxoSmithKline | Toms River |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | Toms River |
| Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease | Phase 2 | Lighthouse Pharmaceuticals, Inc. | Toms River |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | Toms River |
| The Use of AR / VR in Patients Presenting to the ED With Renal Colic | N/A | Community Medical Center, Toms River, NJ | Toms River |
| CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management | — | Hackensack Meridian Health | Totowa |
| Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs | — | SpotitEarly | Totowa |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | Totowa |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Phase 3 | Amgen | Trenton |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma | Phase 3 | Pfizer | Union City |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Phase 3 | Alliance for Clinical Trials in Oncology | Vineland |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | Voorhees Township |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | Voorhees Township |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | N/A | M.D. Anderson Cancer Center | Voorhees Township |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Phase 2/3 | Novartis Pharmaceuticals | Voorhees Township |
| PROton Therapy for Post Surgical Treatment of GYNecologic Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | Voorhees Township |
| Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | N/A | AtaCor Medical, Inc. | Voorhees Township |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | Voorhees Township |
| Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | Voorhees Township |
| Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. | N/A | Pacific Edge Limited | Voorhees Township |
| Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden | Phase 3 | Novartis Pharmaceuticals | Voorhees Township |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | Warren Township |
| A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Phase 3 | Eli Lilly and Company | Warren Township |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | Warren Township |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | Warren Township |
| LRG GIST Patient Registry | — | The Life Raft Group | Wayne |
| A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | — | Bristol-Myers Squibb | West Long Branch |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | MapLight Therapeutics | West Long Branch |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | West Long Branch |
| A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus | Phase 3 | AstraZeneca | West Long Branch |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | Phase 1 | UCB Biopharma SRL | West Long Branch |
| PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | Phase 4 | Aurinia Pharmaceuticals Inc. | West Long Branch |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | West New York |
| Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS | N/A | Kessler Foundation | West Orange |
| Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis | Phase 3 | Medipost, Inc. | Westwood |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | Westwood |
| A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide | — | Bayer | Whippany |
| Transcranial Direct Current Stimulation for Depression | N/A | Soterix Medical | Woodbridge |